ABG
Ally Bridge Group Portfolio holdings
AUM
$114M
This Quarter Return
-11.14%
1 Year Return
+41.64%
3 Year Return
+246.39%
5 Year Return
–
10 Year Return
–
AUM
$286M
AUM Growth
+$286M
(-6.2%)
Cap. Flow
+$17.2M
Cap. Flow
% of AUM
6.02%
Top 10 Holdings %
Top 10 Hldgs %
53.89%
Holding
37
New
6
Increased
5
Reduced
8
Closed
5
Top Buys
| 1 |
ISO
IsoPlexis Corporation Common Stock
ISO
|
$16.3M |
| 2 |
Sarepta Therapeutics
SRPT
|
$10.8M |
| 3 |
Guardant Health
GH
|
$10.5M |
| 4 |
Lantheus
LNTH
|
$9.53M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$5.02M |
Top Sells
| 1 |
Gossamer Bio
GOSS
|
$7.92M |
| 2 |
Viridian Therapeutics
VRDN
|
$5.93M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
$5.68M |
| 4 |
MacroGenics
MGNX
|
$5.38M |
| 5 |
AMRS
Amyris Inc.
AMRS
|
$4.84M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $25M | 8.75% | 268,000 | – | – |
|
2
Arvinas
ARVN
$568M
| $18.9M | 6.6% | 230,000 +20,000 | +10% | +$1.64M |
|
3
Repligen
RGEN
$6.88B
| $18.5M | 6.48% | 70,000 | – | – |
|
|
ISO
4
DELISTED
IsoPlexis Corporation Common Stock
ISO
| $16.3M | 5.69% | +1,770,118 | New | +$16.3M |
|
5
Fate Therapeutics
FATE
$120M
| $15.8M | 5.52% | 270,000 | – | – |
|
6
Cogent Biosciences
COGT
$1.69B
| $12.9M | 4.5% | 1,501,591 -121,000 | -7% | -$1.04M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $12.5M | 4.36% | 85,000 -10,000 | -11% | -$1.47M |
|
|
8
Viridian Therapeutics
VRDN
$1.5B
| $12M | 4.18% | 604,774 -300,204 | -33% | -$5.93M |
|
|
SYRS
9
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $11.5M | 4.03% | 3,539,895 +100,000 | +3% | +$326K |
|
|
10
Sarepta Therapeutics
SRPT
$1.78B
| $10.8M | 3.78% | +120,000 | New | +$10.8M |
|
|
11
Guardant Health
GH
$8.41B
| $10.5M | 3.67% | +105,000 | New | +$10.5M |
|
12
Nuvation Bio
NUVB
$1.02B
| $10.2M | 3.56% | 1,197,152 -463,795 | -28% | -$3.94M |
|
13
IDEAYA Biosciences
IDYA
$2.15B
| $10.2M | 3.55% | 430,000 -145,940 | -25% | -$3.45M |
|
|
14
Lantheus
LNTH
$3.73B
| $9.53M | 3.33% | +330,000 | New | +$9.53M |
|
|
SLGC
15
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $9.31M | 3.25% | 800,000 | – | – |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $9.2M | 3.21% | 550,000 +300,000 | +120% | +$5.02M |
|
|
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.81M | 2.73% | 185,000 | – | – |
|
18
Iovance Biotherapeutics
IOVA
$807M
| $7.77M | 2.72% | 406,986 | – | – |
|
19
Intellia Therapeutics
NTLA
$1.22B
| $7.69M | 2.69% | 65,000 | – | – |
|
20
Nautilus Biotechnolgy
NAUT
$85.9M
| $6.35M | 2.22% | 1,225,060 -274,940 | -18% | -$1.42M |
|
21
Sight Sciences
SGHT
$213M
| $6.01M | 2.1% | 342,304 | – | – |
|
22
Leap Therapeutics
LPTX
$12M
| $5.88M | 2.06% | 1,815,000 +615,000 | +51% | +$1.99M |
|
|
23
Gossamer Bio
GOSS
$562M
| $5.37M | 1.88% | 475,000 -700,000 | -60% | -$7.92M |
|
|
JNCE
24
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $4.8M | 1.68% | +575,000 | New | +$4.8M |
|
25
Rapid Micro Biosystems
RPID
$107M
| $4.66M | 1.63% | 437,960 | – | – |
|